On the N-nitroso-isoxsuprine and N-nitroso-lorcaserin deletion:
Lorcaserin is no longer a marketed API in the US since 2020 I believe, for isoxsuprine there was a stop distribution from FDA in 2021.
So from that perspective it could give a contradictory message to have the NDSRIs in the list.
Cidoxepin NDSRI was not removed, I understand this API was developed in the ’60 but never marketed, but here you probably have to read the entry as an isomer of the doxepin NDSRI (cis instead of trans double bond).